Text Size

Efficacy of Pancrelipase on Postprandial Belching and Bloating.

This study has been completed.
Sponsor:
Information provided by:
Minneapolis Veterans Affairs Medical Center
ClinicalTrials.gov Identifier:
NCT00266721
First received: December 15, 2005
Last updated: NA
Last verified: December 2000
History: No changes posted
  Purpose

The hypothesis of this study is that the administration of pancrelipase with meals will benefit symptoms of post-prandial bloating, pain and eructation.


Condition Intervention Phase
Postprandial Bloating
Postprandial Belching
Postprandial Eructation
 Drug: Pancrelipase (Creon) 2 tablets with each meal
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: Abdominal Pain Gas
U.S. FDA Resources

Further study details as provided by Minneapolis Veterans Affairs Medical Center:

Primary Outcome Measures:
  • Abdominal bloating
  • Abdominal pain
  • Eructation

Estimated Enrollment: 45
Study Start Date: January 2000
Estimated Study Completion Date: October 2000
Detailed Description:

Subjects will complete a double-blind crossover study in which, for one week periods, they will receive two pancrelipase tablets with each of the three major meals or a similarly administered identical placebo. Three times daily, subjects will rate the severity of belching, epigastric discomfort, epigastric fullness, bloating, and nausea.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects will have either bothersome upper abdominal discomfort, bloating (feeling of abdominal distention) or belching following meals for at least 12 month's duration. Subjects must have had a normal upper gastrointestinal endoscopy and/or upper GI series during the preceding three years.

Exclusion Criteria:

  • Individuals with a history suggestive of organic disease such as recent weight loss, nausea, vomiting, GERD, recent changes in bowel habits will be excluded from the study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00266721

Locations
United States, Minnesota
VAMC
Minneapolis, Minnesota, United States, 55417
Sponsors and Collaborators
Solvay Pharmaceuticals
Investigators
Principal Investigator: Michael D Levitt, MD Minneapolis VAMC
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00266721     History of Changes
Other Study ID Numbers: 2355
Study First Received: December 15, 2005
Last Updated: December 15, 2005
Health Authority: United States: Federal Government

Keywords provided by Minneapolis Veterans Affairs Medical Center:
Pancrelipase
Abdominal bloating
Abdominal pain
Eructation

Additional relevant MeSH terms:
Eructation
Signs and Symptoms, Digestive
Signs and Symptoms
Pancrelipase
 Pancreatin
Gastrointestinal Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 21, 2013